2 Biopharma Stocks Expected to Skyrocket

Analysts predict gains of more than 70% for CLLS and EIDX stocks

Jul 16, 2018 at 12:54 PM
    facebook X logo linkedin

    The shares of biopharmaceutical companies Cellectis SA (NASDAQ:CLLS) and Eidos Therapeutics Inc (NASDAQ:EIDX) are higher today, with help from some upbeat analyst attention. Both CLLS and EIDX received new "overweight" ratings, and the brokerage firms set price targets that imply expected upside of more than 70%.

    Barclays Sees Record Highs Ahead for Cellectis

    Specifically, Barclays initiated coverage of Cellectis stock with an "overweight" endorsement and a $50 price target -- a premium of 76% to the security's close of $28.35 on Friday, and in uncharted territory. The analysts waxed optimistic on the cell therapy specialist's partnerships with Allogene and Calyxt, the latter of which could provide additional upside in the form of agricultural opportunities. Further, Barclays sees a "reasonable chance of clinical success for UCART19," and believes off-the-shelf CAR-Ts are "the future of CAR-T therapy."

    CLLS stock is up 4.3% to trade at $29.57, at last check. The shares have been in a channel of higher highs and lows since late 2016, nearly doubling in that time frame. With today's push higher, Cellectis stock is poised to end the session back in the black for 2018.

    CLLS stock chart july 16

    Despite the equity's long-term uptrend, short sellers have been piling on in recent weeks. Short interest on CLLS jumped more than 38% in the past two reporting periods. However, these bearish bets make up less than 2% of the security's total available float.

    Analysts Weigh In On Wall Street Rookie EIDX

    Eidos Therapeutics stock is up 2.1% to trade at $21.20. The shares went public not even one month ago, debuting at $20 -- above their initial public offering (IPO) price of $17. After exploring a range of $18.10 to $24.75 on its first day of trading, EIDX stock has since traded mostly in the $20-$23 range.

    EIDX stock chart july 16

    Today, Barclays and J.P. Morgan Securities initiated coverage of Eido with "overweight" ratings and respective price targets of $32 and $36. The latter target represents expected upside of 73% to EIDX's close of $20.77 on Friday.


    Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

    This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

    On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

    Start targeting gains like the ones our subscribers have seen recently, including:

    213.3% GAIN on AutoNation calls
    100.0% GAIN on Monster Beverage calls
    100.4% GAIN on Walgreens Boots Alliance puts
    100.4% GAIN on ON Semiconductor calls
    257.7% GAIN on Dell calls

    101.0% GAIN on Apollo Global Management calls
    103.6% GAIN on JP Morgan  Chase calls
    105.3% GAIN on DraftKings calls
    101.3% GAIN on Airbnb calls
    203.0% GAIN on Shopify calls
    102.0% GAIN on Cboe Global Markets calls
    100.9% GAIN on Boeing calls
    102.1% GAIN on Microsoft puts
    102.3% GAIN on First Solar calls
    101.5% GAIN on PulteGroup calls
    101.0% GAIN on Apple calls
    209.4% GAIN on NXP Semiconductors calls
    100.8% GAIN on Uber Technologies calls
    100.4% GAIN on Academy Sports and Outdoors puts
    102.2% GAIN on Trade Desk calls
    100.8% GAIN on DoorDash calls
    100.0% GAIN on Camping World Holdings puts
    100.0% GAIN on Cboe Global Markets calls
    100.2% GAIN on C3.ai calls
    238.5% GAIN on Oracle calls



    Rainmaker Ads CGI